Two Sigma Advisers LP boosted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 18.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,069,296 shares of the medical research company’s stock after purchasing an additional 315,600 shares during the period. Amgen makes up 1.1% of Two Sigma Advisers LP’s portfolio, making the stock its biggest position. Two Sigma Advisers LP’s holdings in Amgen were worth $402,830,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Family Legacy Inc. grew its holdings in Amgen by 1.6% during the 4th quarter. Family Legacy Inc. now owns 10,941 shares of the medical research company’s stock valued at $2,130,000 after purchasing an additional 169 shares in the last quarter. Susquehanna Fundamental Investments LLC grew its holdings in Amgen by 1.0% during the 4th quarter. Susquehanna Fundamental Investments LLC now owns 20,719 shares of the medical research company’s stock valued at $4,033,000 after purchasing an additional 203 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its holdings in Amgen by 8.1% during the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 8,019 shares of the medical research company’s stock valued at $1,561,000 after purchasing an additional 604 shares in the last quarter. Brandywine Global Investment Management LLC grew its holdings in Amgen by 2.6% during the 4th quarter. Brandywine Global Investment Management LLC now owns 780,307 shares of the medical research company’s stock valued at $151,903,000 after purchasing an additional 19,528 shares in the last quarter. Finally, JT Stratford LLC grew its holdings in Amgen by 367.5% during the 4th quarter. JT Stratford LLC now owns 8,424 shares of the medical research company’s stock valued at $1,640,000 after purchasing an additional 6,622 shares in the last quarter. 79.18% of the stock is owned by institutional investors and hedge funds.
Shares of AMGN stock opened at $188.05 on Wednesday. The firm has a market cap of $115.83 billion, a price-to-earnings ratio of 13.06, a P/E/G ratio of 2.34 and a beta of 1.21. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36. Amgen, Inc. has a 1-year low of $165.22 and a 1-year high of $210.19.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.26 by $0.16. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 66.74%. During the same period last year, the business earned $2.89 EPS. Equities analysts forecast that Amgen, Inc. will post 13.96 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a $1.45 dividend. The ex-dividend date is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.08%. Amgen’s payout ratio is currently 40.28%.
In other news, Director Ronald D. Sugar sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $193.18, for a total value of $386,360.00. Following the transaction, the director now directly owns 15,092 shares in the company, valued at approximately $2,915,472.56. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 6,000 shares of company stock worth $1,144,120. Insiders own 0.27% of the company’s stock.
A number of equities research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. Goldman Sachs Group reaffirmed a “buy” rating and set a $232.00 price target on shares of Amgen in a report on Thursday, January 17th. Oppenheimer set a $224.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Sunday, January 27th. Royal Bank of Canada reaffirmed a “neutral” rating and set a price target on shares of Amgen in a report on Monday, January 14th. Finally, Citigroup raised their price target on shares of Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a report on Friday, January 4th. Eleven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $209.11.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Put Option
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.